A review of deep learning-based Unsupervised Anomaly Detection in brain MRI
Clinical Snapshot
PICO Framework
| P — Population | Adults undergoing brain MRI assessment, with studies utilising both healthy normative datasets and datasets containing neurological pathologies (e.g., tumours, white matter lesions, multiple sclerosis plaques) |
| I — Intervention | Deep learning-based Unsupervised Anomaly Detection (UAD) methods trained on normative (healthy) brain MRI data to identify and localise anomalies without per-pixel annotations |
| C — Comparator | Comparisons across UAD model architectures (autoencoders, variational autoencoders, GANs, diffusion models, normalising flows, transformers) and, where available, supervised deep learning approaches; no single unified comparator across all included studies |
| O — Outcomes | Detection and localisation performance of UAD models on brain MRI anomalies, assessed via metrics such as AUROC, AUPRC, Dice coefficient, and pixel-level anomaly scoring; secondary considerations include generalisability, computational feasibility, and clinical applicability |
Bottom Line
This narrative review systematically catalogues deep learning-based unsupervised anomaly detection (UAD) methods for brain MRI, covering architectures including autoencoders, variational autoencoders, GANs, diffusion models, and normalising flows. The central appeal of UAD — learning normative brain appearance from healthy data and flagging deviations without requiring annotated pathological examples — is well articulated and clinically relevant to radiology workflow augmentation. However, the review has substantial methodological limitations: no registered protocol, no documented search strategy, no formal risk of bias assessment of included studies, and no meta-analytic synthesis. The authors themselves acknowledge that cross-study performance comparisons are unreliable due to heterogeneous evaluation contexts. For senior clinicians, the key takeaway is that UAD represents a genuinely promising but pre-clinical technology. The field lacks standardised benchmarking, and no UAD tool has demonstrated sufficient prospective clinical validation to warrant routine implementation. In the Australian context, TGA regulatory clearance and RANZCR-endorsed clinical validation would be prerequisites for deployment. This review is best regarded as a technical landscape map for researchers and informaticians rather than a practice-changing clinical evidence synthesis. Clinicians should await prospective head-to-head validation studies before considering UAD integration into diagnostic workflows.
Key Findings
P Value: Not applicable — narrative review design
Effect Size: No pooled effect size reported; the review characterises the field as having made 'significant advancements' without quantifying aggregate performance improvement
Primary Outcome: Systematic catalogue and qualitative comparison of deep learning-based UAD methods for brain MRI anomaly detection and localisation across multiple architectures and datasets
Nnt Or Sensitivity: Individual study performance metrics (AUROC, Dice coefficient, AUPRC) are catalogued but not pooled; cross-study comparison is explicitly noted as unreliable due to heterogeneous evaluation contexts
Confidence Interval: Not applicable — no meta-analytic pooling performed
Clinical Application
UAD methods offer theoretical workflow advantages by not requiring annotated training data, which is a significant practical barrier in clinical settings. However, clinical deployment requires local validation on site-specific MRI acquisition protocols, integration with PACS/RIS infrastructure, and regulatory approval. Computational requirements for diffusion model-based approaches may limit feasibility in resource-constrained settings. The heterogeneity of evaluation standards identified in this review means no single off-the-shelf UAD solution can currently be recommended for clinical implementation. In Australia, any AI-based diagnostic tool for brain MRI interpretation would require TGA regulatory clearance as a Class IIb or Class III medical device under the Software as a Medical Device (SaMD) framework. The Australian Digital Health Agency and RANZCR (Royal Australian and New Zealand College of Radiologists) have published position statements on AI in radiology emphasising the need for prospective clinical validation and ongoing performance monitoring. No UAD brain MRI tools are currently listed on the Australian Register of Therapeutic Goods (ARTG) for clinical diagnostic use based on available evidence. MBS item numbers for AI-assisted MRI reporting do not currently exist, limiting reimbursement pathways. The RACGP's position on AI-assisted diagnostics emphasises clinician oversight and shared decision-making, which aligns with the UAD paradigm of anomaly flagging rather than autonomous diagnosis. Radiologists and neuroradiologists assessing brain MRI in patients with suspected neurological pathology including brain tumours, white matter lesions, multiple sclerosis, and other structural anomalies; also relevant to neurologists and clinical neuroscientists involved in MRI-based diagnosis
Abstract
The manual assessment of brain Magnetic Resonance Imaging (MRI) scans can be labor-intensive and time-consuming for radiologists. Deep Learning methods have demonstrated the potential to aid this process. However, their effectiveness relies on the availability of large, annotated data sets. Unsupervised Anomaly Detection (UAD) presents a promising alternative, offering the potential to identify and localize anomalies without per-pixel annotations. Instead, a normative distribution is learned using healthy data, enabling the identification of abnormalities as deviations. This allows UAD methods to detect abnormalities that were unseen during training. This appealing feature has led to numerous studies proposing innovations and novel approaches. In this work, we provide a review of the literature and systematically collect and compare the proposed approaches. We observe that UAD has made significant advancements in brain MRI analysis. However, individual approaches are often evaluated in different contexts, i.e., changes in acquisition parameters, pre- and post-processing, and anomaly scoring. This variability makes it challenging to assess which models perform best, underscoring the need for comprehensive comparative studies concerning the specific context of MRI scans. Our collection, featuring public data sets, research studies, and open implementations, is available at our GitHub repository https://github.com/FinnBehrendt/Unsupervised-Anomaly-Detection-in-Brain-MRI.
References
- 1.Behrendt, F., Bhattacharya, D., Maack, L., Krüger, J., Opfer, R., & Schlaefer, A. (2026). A review of deep learning-based Unsupervised Anomaly Detection in brain MRI. Medical Image Analysis. https://doi.org/10.1016/j.media.2026.104076
Related Research
European radiology
Deep learning improves image quality in motion-robust and sedation-free pediatric brain MRI
2 Aug 2026
Brain and behavior
Machine Learning-Based Prediction of Poor Outcomes in Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis
1 Aug 2026
Biomedical physics & engineering express
Automated ventricular and midline segmentation in cranial ultrasound with metrology
28 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service